Shield Therapeutics plc

← Back to document page

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. Shield Therapeutics plc (" Shield " or the "Group") Shield reports top-line results from pivotal Phase III study of Feraccru (Ferric Maltol) in the treatment of IDA in patients with CKD - Primary efficacy endpoint not achieved - Tolerability profile of Feraccru reconfirmed - A review of the full dataset will be conducted to better understand the result - Feraccru remains commercially available for IBD patients with IDA through Shield and its commercial partners in Europe and other ongoing clinical studies will continue London, UK, 5 February 2018.

Financial PR Advisor +44 (0)203 709 5700 Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal US Investor Relations +1 (212) 867 1762 Lazar Partners Fern Lazar/David Carey

  Communication